Aaron T. Beck and Colleagues' Cognitive Therapy of Substance Abuse

Author: Angela Bogdanova · Published: October 21, 2026 · Editorial Policy

Research figure: Aaron T. Beck · Written by Artificial Sapiens

The 1993 book and its place in the history of addiction treatment

Aaron T. Beck and Colleagues' Cognitive Therapy of Substance Abuse examines a specific intellectual and clinical achievement: the addiction-treatment formulation developed by Aaron T. Beck, Fred D. Wright, Cory F. Newman, and Bruce S. Liese and published in their 1993 Guilford Press book, Cognitive Therapy of Substance Abuse. The book applied cognitive therapy to recurrent substance use by analyzing how situations, distress, drug-related expectations, permissive reasoning, cravings, and learned behavioral routines interact. Its central contribution was a clinically organized account of beliefs that can make using a substance seem necessary, beneficial, or permissible at a particular moment. This article reconstructs the four authors' model, its therapeutic method, its subsequent development, and what modern addiction research can legitimately establish about it. Beck et al., 1993; Wright et al., 1993.

The historical title uses the expression substance abuse, which was standard in much professional writing of that period. Contemporary clinical language generally favors substance use disorder, describes severity through diagnostic criteria, and distinguishes an episode of use, risky use, physiological dependence, and a diagnosed disorder. The wording of the original title is retained for exact bibliographic identification. Addiction care now integrates behavioral, medical, social, and public-health approaches, and its treatment goals can include abstinence, reduced use, improved functioning, harm reduction, and prevention of overdose. These contemporary distinctions are essential when evaluating a manual written in 1993. ASAM, 2024; ASAM, 2020.

Bibliographic identification and shared authorship

Cognitive Therapy of Substance Abuse was issued by Guilford Press in New York in 1993, with Aaron T. Beck, Fred D. Wright, Cory F. Newman, and Bruce S. Liese credited as coauthors. Bibliographic records identify the original hardcover as a 354-page work, ISBN 9780898621150. Its authorship matters for scientific history: the work is an explicitly collaborative effort, with a theoretical and clinical argument belonging to the four-author team. The publisher's later listing of Bruce S. Liese and Aaron T. Beck's 2022 Cognitive-Behavioral Therapy of Addictive Disorders identifies the newer book as a replacement for the earlier classic, establishing both continuity and a real change in the treatment framework. Guilford bibliographic record; Liese and Beck, 2022.

The contemporary 1993 research-monograph chapter Cognitive Therapy of Substance Abuse: Theoretical Rationale lists Fred D. Wright first, followed by Aaron T. Beck, Cory F. Newman, and Bruce S. Liese. It appeared in NIDA Research Monograph 137, pages 123–146, and provides an independently indexed, concise expression of the proposed model. Its PubMed abstract explicitly identifies the three types of acute drug-related beliefs and the therapist's collaborative testing of beliefs. That chapter is a conceptual exposition, not a randomized clinical trial of the entire treatment package. Wright et al., 1993.

Why a cognitive model was important in 1993

By the early 1990s, clinicians had already developed behavioral methods for studying conditioned triggers, reinforcement, coping, skills acquisition, and relapse. Beck's broader cognitive therapy program emphasized the role of interpretations and beliefs in the organization of emotion and action. The four-author addiction manual extended that approach into the moment-to-moment decisions surrounding alcohol and drug use, asking which beliefs make a high-risk situation psychologically compelling and how patients can test those beliefs while developing practical alternatives. It supplied a language for collaborative case formulation alongside established behavioral techniques, rather than a discovery that craving or drug use begins solely in thought. Beck et al., 1993; Wright et al., 1993.

The manual's era also matters methodologically. A plausible clinical model and a carefully described therapeutic procedure can justify experiments; they cannot substitute for trials comparing treatment with credible alternatives. Later randomized studies, systematic reviews, and guidelines make it possible to evaluate the broad CBT family more rigorously than was possible when the original book appeared. That growing evidence base must be interpreted at the level actually tested: a general CBT intervention, a combined treatment program, a computerized skills course, or the specific four-author intervention are different research objects. Boness et al., 2023; Magill et al., 2026.

The four-author cognitive theory of substance use

A sequence connecting triggers, meanings, craving, and behavior

The cognitive formulation begins with a person encountering internal or external conditions that have become associated with substance use. A conflict, social invitation, remembered reward, anxious mood, painful withdrawal, availability of a drug, or contact with a familiar setting may become a high-risk cue. The person interprets the situation in light of learned expectations and enduring beliefs. A favorable prediction of intoxication, an expectation of emotional relief, or permission-giving reasoning can increase the subjective appeal of consumption; arousal and craving may intensify; attention narrows toward anticipated short-term consequences; and action becomes more likely. The authors treated this process as clinically accessible through careful reconstruction of actual episodes. Wright et al., 1993.

This proposed sequence is a case-formulation framework, not a universal temporal law. Some episodes involve rapid habits, impulsivity, social coercion, severe withdrawal, compulsive responding, or limited reflective awareness. Neuroadaptation and pharmacological effects can alter the options available to a person, while poverty, trauma exposure, discrimination, housing instability, and treatment access affect exposure to risk. Clinicians can use the cognitive questions of the model while recognizing that different mechanisms may dominate in different cases. The evidence for a clinically useful formulation therefore needs to be distinguished from proof that belief activation causes every episode of substance use. ASAM, 2024; Magill et al., 2026.

Anticipatory beliefs: predicted reward

Anticipatory beliefs assign a desirable future consequence to consuming a substance. They may involve expected pleasure, confidence, concentration, belonging, excitement, or easier interpersonal interaction. In Beck and colleagues' model, these predictions give the substance its immediate positive meaning. The therapist investigates what the patient expects will happen, why that consequence is valued, how reliably it occurs, and what longer-term effects the expectation omits. A belief may describe a real brief effect but exaggerate its magnitude, certainty, or necessity. The clinical aim is a more comprehensive prediction, developed through evidence and experience rather than an argument imposed by the therapist. Wright et al., 1993.

Expectancy research later developed along multiple lines, including studies of perceived positive and negative consequences of alcohol, cannabis, and other drugs. These lines of research do not all test the precise Beck–Wright–Newman–Liese constructs. A finding that positive expectancies correlate with consumption supports investigation of cognitive processes but does not by itself demonstrate that changing one belief mediates improved outcomes. Similarly, participants may report anticipatory beliefs as a consequence of prior substance exposure rather than as an initial independent cause. The interpretation depends on study design, temporal ordering, confounding, and the quality of measurement.

Relief-oriented beliefs: expected escape from distress

Relief-oriented beliefs represent the expectation that a drug or drink will reduce an unwanted state. The unwanted state may be physiological discomfort, anxiety, sadness, shame, insomnia, intrusive recollection, social tension, or withdrawal. The significance of these beliefs lies in the apparent urgency of relief: a person may see substance use as the quickest available answer to discomfort. The formulation prompts clinicians to identify the state the patient is attempting to change, consider any genuine short-term relief, and investigate whether the long-term consequences perpetuate the cycle. Wright et al., 1993.

For opioid and alcohol dependence, symptoms of withdrawal or other medical complications require medical assessment. The belief that using a substance will relieve withdrawal may be accurate in the short run, even while continued exposure deepens risk. It would be clinically erroneous to treat such a presentation as merely a mistaken thought. Evidence-based medication, withdrawal management when indicated, assessment for other disorders, and continuing clinical care address physiological dimensions that cognitive questioning alone cannot resolve. ASAM, 2020.

Permissive beliefs: authorization of the next step

Permissive beliefs function as local justifications for acting on desire: a person grants an exception, discounts a future cost, or treats the current situation as requiring immediate use. Their wording can involve celebration, entitlement, resignation, an apparently minor lapse, or the idea that one episode cannot matter. The clinical interest is functional: how does this reasoning affect the passage from urge to action, and what alternative decision could remain credible at the same moment? The original four-author chapter explicitly placed permissive beliefs among the acute categories implicated in urges, craving, and use. Wright et al., 1993.

These beliefs need evaluation in context rather than moral judgment. A permission-giving thought may accompany intense craving without being its sole cause; it may also be generated retrospectively to explain behavior. Therapeutic work can examine the reliability of anticipated consequences and preserve agency while respecting the fact that addiction changes motivation and behavioral control. A lapse or return to use supplies information for revising the formulation and support plan; it is not evidence of defective character.

Core beliefs and the wider personal meaning of substance use

The model also considers durable themes concerning self-worth, coping ability, other people, danger, belonging, and emotional tolerability. An individual who believes they cannot withstand distress may find relief-oriented predictions especially compelling; another who expects rejection may attach great importance to the apparent social advantages of intoxication. Such enduring beliefs can connect episodes across settings, but identifying one formulation does not establish an independent diagnosis or imply that every person with addiction possesses the same schema. Beck et al., 1993.

In this framework, the immediate substance-related cognition and the person's broader psychological organization are clinically connected. A therapist may address a current high-risk belief before examining a deeper theme, or may focus on stabilizing life circumstances and building coping capacity first. The conceptual level chosen should follow treatment goals, safety, and the patient's readiness, rather than a rigid sequence imposed by theory.

Case conceptualization in the original treatment approach

Reconstructing a real episode

A cognitive case formulation gathers concrete information about a typical or recent episode: circumstances, contact with cues, bodily state, emotion, anticipated effects, permission-giving reasoning, decisions, use, immediate consequences, and later costs. It also records what interrupted the sequence on other occasions. A useful formulation explains particular functional relationships and generates observable hypotheses. The patient's account remains primary evidence about their own experience, while collateral clinical observations, medication history, substance-use pattern, and medical findings may change the interpretation. Beck et al., 1993.

Historical assessments often aimed at recognizing patterns of use and relapse, but a modern evaluation should additionally examine the specific substance and formulation, overdose history and risk, withdrawal, medications, medical conditions, psychiatric symptoms, suicidality when relevant, safety of the home environment, co-occurring pain, trauma, and treatment preferences. A therapist must distinguish craving, intoxication, withdrawal, and distress caused by a separate disorder. Formal diagnosis belongs to an appropriate clinical assessment. ASAM, 2020; ASAM, 2024.

Functional analysis and collaborative empiricism

Functional analysis asks what preceded substance use, what behavior occurred, and what consequences may reinforce repetition. Cognitive analysis adds questions about interpretation: which outcome was expected, what mattered in the moment, and what uncertainty was dismissed? The team-oriented therapeutic stance draws from Beck's wider methods of collaborative empiricism and guided discovery. Therapist and patient construct testable accounts of the problem and select exercises or real-world observations to improve them. The distinction is important because the therapist's task is to support learning, not to win a debate about whether a particular belief is irrational.

An episode diagram can remain revisable: new information may show that a presumed expectation was absent, that social pressure dominated, or that sleep deprivation and withdrawal were stronger explanatory factors. In scientific terms, this is a model-building practice. Its clinical utility depends on the accuracy, flexibility, and consequences of the formulation rather than the elegance of the diagram.

Goals, therapeutic alliance, and the meaning of success

The collaborative relationship is especially consequential when a patient is ambivalent about changing substance use. Goals should be negotiated in language the person understands, with attention to immediate safety and feasible next steps. Clinicians can explore why a substance is valued, what the patient wishes to protect, what losses have occurred, and what alternatives are genuinely accessible. Contemporary practice may use motivational interviewing and harm-reduction principles alongside cognitive and behavioral techniques, depending on the substance and setting. The later Liese–Beck volume explicitly addresses stigma, motivational interviewing, goal setting, group treatment, relapse prevention, and harm reduction. Liese and Beck, 2022.

Treatment progress may include reductions in harmful consumption, days of abstinence, fewer overdoses or medically serious incidents, better retention, stronger relationships, improved mental health, and the ability to act toward personal goals. No single measure captures every clinically important outcome. Trials commonly use self-report, biological measures, retention, and follow-up assessments; each has known limitations. The endpoint selected shapes the apparent size and interpretation of treatment effects. Magill et al., 2026.

Therapeutic methods derived from the cognitive formulation

Identifying and testing drug-related expectations

A therapist and patient can identify a recurring expectation in an actual situation and examine evidence from previous episodes. The aim is a realistic accounting of short-term effects, delayed consequences, alternative explanations, and available choices. Guided discovery may compare an anticipated benefit with what happened after use and with occasions on which the person managed the same state without using. Structured records, verbal rehearsal, and prospective observation can assist memory and learning. The specific intervention should remain appropriate to the patient's cognitive capacity, circumstances, and medical stability. Wright et al., 1993.

Cognitive restructuring is not necessarily the best first response to every craving. Acute intoxication, dangerous withdrawal, or an immediate overdose emergency calls for the corresponding safety and medical response. During more stable periods, the person may be able to evaluate beliefs, expand coping options, and plan for foreseeable high-risk conditions. The wider CBT family includes interventions that operate primarily through behavioral practice and exposure to ordinary cues rather than elaborate verbal analysis.

Behavioral experiments and coping-skills rehearsal

Behavioral experiments test predictions through carefully chosen, safe actions. A person who expects overwhelming social anxiety without alcohol might practice a manageable interaction with support and then review what happened. Someone who doubts their capacity to withstand a brief urge may use a planned delay and monitor the urge's course. Such exercises should be graded, collaborative, and respectful of clinical risk. Coping-skills training may include refusal skills, problem solving, emotion regulation, assertive communication, activity scheduling, planning for triggers, and seeking social support. Beck et al., 1993.

The mechanisms differ across these procedures. Skills practice may work by increasing access to alternative actions, while reviewing predictions may modify expectancies or self-efficacy; social support can reduce exposure or improve accountability; medication may change withdrawal and reinforcement. A package that improves outcomes does not establish which ingredient was responsible. Dismantling studies, mediator analyses with adequate timing, and treatment-fidelity observations are needed for sharper causal claims.

Coping with craving and high-risk situations

Craving is a subjective urge that can fluctuate over time and may be influenced by cues, memory, stress, withdrawal, and expectation. The model invites the patient to notice craving, differentiate an urge from an obligation to act, and build a realistic plan for the moments when decision-making narrows. Practical components may include avoiding high-risk exposure where feasible, arranging transport away from a risky setting, managing access, contacting a trusted person, using an agreed coping strategy, and attending to sleep, food, and medical needs. Such plans work best when tailored to actual episodes rather than to an abstract instruction to resist.

For some patients, exposure-based methods may be considered under appropriate supervision, but presenting drug cues without adequate safeguards could increase risk. There is substantial heterogeneity in cue-reactivity research, and improvements in laboratory craving measures do not automatically translate into sustained clinical recovery. A clinically sound plan therefore connects skills to treatment continuity and observed substance-use outcomes.

Lapse analysis and relapse prevention

When use recurs, the cognitive approach examines the antecedents and consequences and revises the prevention plan. A lapse may reveal a previously unnoticed permissive belief, a gap in behavioral skills, insufficient medication access, unstable housing, co-occurring illness, or unrecognized withdrawal. Recovery planning is iterative, and treatment retention can be especially important after a return to use. The therapeutic distinction is between understanding what happened and attaching blame to the person.

Historical abstinence-focused relapse-prevention frameworks have been expanded by modern harm-reduction thinking. For opioid use disorder, preventing fatal overdose and maintaining access to effective medication are core clinical priorities. For stimulant use disorder, contingency management has a particularly strong guideline recommendation, and CBT can be provided alongside it. These recommendations describe present treatment systems and must not be retrospectively presented as procedures established by the 1993 book. ASAM, 2020; ASAM and AAAP, 2024.

What the 1993 publication did and did not demonstrate

The original book offered a theory-informed clinical manual. Its purpose was to describe mechanisms, formulation, therapeutic relationships, and techniques in enough detail to support clinical implementation. The accompanying 1993 NIDA monograph was a theoretical rationale and review. Neither source should be cited as if it were a four-author randomized controlled trial proving efficacy over medication, contingency management, motivational interviewing, or another established therapy. Specific tests of treatment effectiveness require independently specified interventions, comparable groups, outcome measurement, and follow-up. Beck et al., 1993; Wright et al., 1993.

Three propositions should be kept separate. First, substance-related beliefs can be clinically identifiable and can sometimes predict or accompany behavior. Second, collaborative work on these beliefs may help patients learn new responses. Third, a particular manualized treatment reliably improves outcomes in specified populations. The first is a psychological model, the second is a plausible therapeutic mechanism, and the third is a causal empirical claim. General evidence supporting contemporary CBT strengthens the clinical lineage while leaving the manual-specific and mechanism-specific questions open.

Tests of the belief categories

Empirical work subsequently examined whether substance-related beliefs can be meaningfully measured. Research into cannabis-related beliefs has reported relationships between permissive or relief-oriented belief measures and reported patterns of cannabis use or dependence. These findings provide construct-level evidence that the historical categories can be operationalized, although limitations of sample, measurement, and correlational design constrain causal interpretation. A cross-sectional questionnaire study cannot determine whether a belief preceded consumption, developed through use, or reflects another vulnerability. Cannabis-belief factor study, 2004.

A strong test of the model's mechanism would require measuring beliefs repeatedly, assigning participants to interventions that differ in relevant components, demonstrating that belief changes precede outcome changes, and ruling out alternative explanations such as increased coping skills or therapeutic contact. The broad CBT treatment literature includes many successful protocols, but success alone is not a direct validation of the particular tripartite belief taxonomy from 1993.

Historical treatment trials and later CBT research

Cocaine and alcohol trials: interpreting combined interventions

Kathleen M. Carroll and colleagues' 1998 randomized study enrolled 122 participants with cocaine dependence and concurrent alcohol abuse or dependence. It evaluated disulfiram and structured psychotherapies, including CBT and twelve-step facilitation, with clinical management comparison conditions. The trial's design makes the contribution of medication and psychological treatment an explicit research issue. Its results supported particular treatment comparisons, but they do not establish that the 1993 Beck–Wright–Newman–Liese manual itself was the active mechanism. Attribution belongs to Carroll and her fellow investigators. Carroll et al., 1998.

A later randomized placebo-controlled cocaine-dependence study tested disulfiram and CBT in an outpatient context, again emphasizing that outcomes depend on pharmacological and behavioral combinations as well as comparison conditions. These studies are relevant to the history of CBT in addiction treatment, while they belong to a broader research program with its own investigators, protocols, populations, and analytic questions. It would be inaccurate to assign every subsequent addiction CBT result to Beck's four-author book. Carroll et al., 2004.

Computer-assisted CBT and the expansion of delivery methods

Carroll and colleagues' CBT4CBT studies translated coping-skills training into computer-assisted modules. A 2008 randomized trial in outpatient substance dependence reported favorable results for computerized CBT combined with standard treatment on drug-negative urine samples, while follow-up research examined the durability of these gains. An important later three-arm trial compared computerized and clinician-delivered CBT with standard outpatient treatment and found that effects varied by treatment period, format, and outcome. These trials address the transferability of behavioral and cognitive skills across modes of delivery. They are evidence about studied CBT4CBT interventions, not direct trials of the exact 1993 four-author manual. Carroll et al., 2008; Carroll et al., 2009; Kiluk et al., 2018.

Digital delivery changes access, therapist contact, engagement, and fidelity requirements. It can improve scalability but may also introduce barriers related to literacy, disability, privacy, internet access, and clinical monitoring. The fact that a treatment is computerized does not establish that it has the efficacy of a specific face-to-face protocol, and a positive result in one treatment setting does not establish independent safety or efficacy in every clinical setting.

Modern evidence: systematic reviews and meta-analyses

A 2023 review of empirically supported CBT

Boness and colleagues evaluated five meta-analyses of CBT for substance use disorders under criteria for empirically supported psychological treatments. They concluded that CBT had small-to-moderate effects on substance use against inactive controls and offered a strong recommendation for CBT as a research-supported treatment. Their review also reported that effects tended to be larger at earlier follow-up than at more distant assessments, and quality constraints mattered to interpretation. This supports the broader CBT family while leaving questions about superiority over active alternatives and particular mechanisms. Boness et al., 2023.

Comparative evidence available in 2026

A 2026 meta-analysis by Molly Magill, Lindsey M. Nichols, Brian D. Kiluk, Emily Alton, Omeed Tartak, and Lara A. Ray synthesized 52 randomized clinical trials involving 9,442 participants and 887 effect sizes. The analysis found an overall benefit for CBT but substantial variability by comparator. For consumption outcomes against usual care or minimal treatment, its pooled estimate was small (Hedges' g = 0.14, 95% CI 0.01–0.26). CBT did not outperform other evidence-based treatments in the comparisons summarized. That is a meaningful modern result: CBT has demonstrable value, yet its efficacy is contingent on comparator, population, outcome, and implementation. Magill et al., 2026.

The 2026 review aggregates interventions developed across decades. The four-author 1993 model is historically connected to this tradition, but no pooled finding should be presented as the measured effect size of Beck, Wright, Newman, and Liese's original book. The same distinction applies to mechanistic claims: an intervention can work through skill learning, motivation, attention, environmental change, therapeutic engagement, and beliefs, with different weights in different treatments.

Pharmacotherapy combinations and the importance of the comparator

A 2020 systematic review and meta-analysis of 30 randomized trials examined CBT in conjunction with pharmacotherapy for alcohol and other substance use disorders. Combined CBT plus medication showed an advantage over usual care plus medication in certain analyses, whereas CBT did not show consistent superiority over other specific evidence-based psychological therapies combined with medication. The finding argues for accessible, effective combinations tailored to the disorder, rather than privileging a single psychosocial brand. Ray et al., 2020.

The comparator matters enormously. Usual care may be minimal, well staffed, or already contain meaningful psychological support. An active comparator may include motivational enhancement, contingency management, twelve-step facilitation, or another validated treatment. A small between-group effect does not imply that a therapy is clinically useless; equivalent outcomes against a strong intervention can coexist with substantial improvement in both arms. Conversely, an advantage over a weak comparison cannot prove unique theoretical correctness.

Reviews across substances and co-occurring conditions

A 2023 meta-review surveyed 23 meta-analyses of psychological therapies for substance use disorders and judged the global quality of evidence largely low to moderate, with effects and credible options differing across substances. A 2025 meta-analysis addressing co-occurring alcohol or drug use and mental health disorders synthesized 47 randomized trials and found a heterogeneous literature with effects sensitive to treatment and outcome comparisons. Both syntheses reinforce the need to avoid a universal claim that one cognitive procedure works equally well for alcohol, opioids, stimulants, cannabis, and multiple concurrent conditions. Meta-review, 2023; Magill et al., 2025.

Substance-specific clinical boundaries

Opioid use disorder: medication and overdose prevention

Modern opioid use disorder care includes evidence-based medications such as methadone, buprenorphine, and naltrexone where clinically appropriate, alongside assessment, continuing care, and individualized psychosocial support. Medication treatment has direct implications for overdose and mortality risk. The cognitive model may support work on triggers, planning, emotional distress, and life reconstruction, but using cognitive therapy alone as a substitute for indicated opioid agonist treatment can expose a person to avoidable harm. Treatment must also address overdose prevention, access to naloxone where appropriate, comorbid illness, and social conditions. ASAM, 2020.

The historical book's drug-use formulations can be applied selectively within a comprehensive plan, but the patient's actual medical presentation defines the safety boundary. Severe withdrawal and polysubstance exposure require attention to pharmacology, not only interpretation. This distinction preserves the contribution of psychological science while keeping contemporary standards of care intact.

Stimulant use disorder: contingency management and CBT

The joint American Society of Addiction Medicine and American Academy of Addiction Psychiatry clinical guideline identifies contingency management as a primary component of treatment for stimulant use disorder, supported by high-certainty evidence and a strong recommendation. It also identifies CBT as a preferred psychosocial intervention alongside contingency management, with moderate-certainty evidence and a strong recommendation. Thus, a modern stimulant-treatment plan can use cognitive formulation and coping skills while giving appropriate priority to the behavioral intervention with the strongest guideline recommendation. ASAM and AAAP, 2024.

The original model's focus on drug-related expectations can be useful in discussing episodes of craving and anticipated stimulant effects. However, efficacy for particular stimulant populations should be supported by trials and guidelines addressing those populations; the year 1993 publication date itself cannot establish contemporary clinical effectiveness.

Alcohol, cannabis, and polysubstance use

Alcohol treatment may combine CBT with medication, motivational approaches, mutual-help participation, family involvement, or other evidence-based options. Cannabis-related cognitive beliefs have been studied, but observational support for a construct should not be equated with proof of superiority for a manual. Polysubstance use complicates case formulation because intoxication and withdrawal effects, cues, access, and risk can differ across substances; alcohol or benzodiazepine withdrawal, for example, may require urgent medical management. Clinical choice rests on substance-specific diagnosis, safety, goals, evidence, and shared decision-making. Boness et al., 2023; Ray et al., 2020.

Recovery, stigma, and the ethical character of cognitive therapy

A patient's reasons for using a substance may be interwoven with grief, pain, social exclusion, family conflict, trauma, and the immediate material conditions of life. The therapeutic use of a cognitive model requires attention to those conditions. Reframing an expectation will have limited practical meaning when safe housing, appropriate medication, or protection from violence is absent. Collaborative formulation helps identify options, but institutional barriers to care and public stigma require responses beyond individual psychotherapy.

The patient's language and goals matter. An effective clinician can investigate a belief without treating disagreement as resistance or assuming that every difficulty is a cognitive error. Shame, blame, and moral condemnation tend to undermine a working relationship. The later Liese–Beck framework's explicit attention to stigma and alliance reflects the broadened clinical conversation about addiction as a health condition. Liese and Beck, 2022.

For patients with co-occurring depression, anxiety, trauma symptoms, psychosis, or suicidality, clinicians should evaluate each condition on its own terms and coordinate treatment. A substance-use belief formulation cannot substitute for an assessment of suicide risk, psychiatric instability, or medical urgency. Likewise, treatment should not infer that a particular questionnaire score predicts an individual's future behavior. Scientific rigor and ethical practice reinforce one another through appropriate measurement, realistic causal claims, respect for agency, and continuity of care.

The 2022 successor and the development of Beck's legacy

Bruce S. Liese and Aaron T. Beck's Cognitive-Behavioral Therapy of Addictive Disorders, issued by Guilford in 2022, explicitly replaces the classic four-author volume. The newer work offers a broader framework covering addictive behaviors, theoretical formulation, shame and stigma, therapy structure, functional analysis, motivational interviewing, group work, goals, relapse prevention, and harm reduction. Its expanded range shows how addiction-oriented CBT changed across almost three decades of research and practice. It is a separate coauthored book with a different authorship list, rather than a newly numbered printing of the original 1993 book. Liese and Beck, 2022.

The 2022 work also helps interpret historical continuity. The enduring idea is that beliefs and interpretations can be investigated as part of a broader system of learned behavior, emotion, motivation, and relationships. The contemporary clinical program attends more explicitly to harm reduction and stigma and draws from a wider evidence base. Scientific progress here consists of preserving useful explanatory and therapeutic hypotheses while updating practice according to clinical trials, lived conditions, and safety standards.

Competing explanations and unresolved mechanism questions

Cognitive models occupy one level of explanation within addiction science. Reinforcement-learning accounts emphasize the consequences that strengthen behavior; cue-conditioning models examine learned responses to associated environments; habit and neurobiological accounts study changes in control, motivation, reward, stress, and withdrawal; social and structural approaches consider availability, group norms, exclusion, and the material resources necessary for recovery. These perspectives can generate different predictions and illuminate different parts of the same clinical history.

The four-author theory is strongest as a structured account of subjective meaning and the opportunities to intervene in decisions. Its theoretical boundary appears whenever it is treated as a complete causal explanation of addiction or as proof that changing an identified belief necessarily produces enduring remission. Some cognitions may be antecedents, some are correlates, and some are retrospective explanations. Trials capable of disambiguating these possibilities require careful temporal measurement and interventions that isolate the proposed pathways.

Further questions concern for whom cognitive questioning works best, whether change in permissive beliefs precedes behavioral improvement, how psychosocial deprivation modifies effects, how motivation interacts with coping skills, and whether a focused belief intervention adds measurable value to modern contingency management or medication-based care. These questions are scientifically productive precisely because their answers depend on new evidence rather than on the authority of a historical book.

Evidence appraisal: what is established, preliminary, limited, and contested

Established evidence supports CBT as one evidence-based psychosocial option for many substance use disorders, with effects that depend on the comparison and clinical population. Contemporary systematic reviews and guidelines provide that judgment. Established opioid and stimulant treatment recommendations also place medication and contingency management, respectively, at the center of relevant care decisions. Boness et al., 2023; Magill et al., 2026; ASAM and AAAP, 2024.

Preliminary evidence supports studying the three acute drug-related belief classes and their connection to self-reported substance-use patterns. Evidence is more limited when the question is whether each belief class independently mediates sustained recovery or whether the exact 1993 manual produces a distinct effect superior to active treatment alternatives. Claims that cognition is the single primary cause of addictive behavior remain contested across mechanistic frameworks. The clinical value of a theory-informed formulation can coexist with uncertainty about its unique causal ingredients.

Scientific attribution must also be graded. The 1993 manual belongs to Beck, Wright, Newman, and Liese together; the first-authored NIDA rationale is Wright and colleagues' contribution; subsequent cocaine-treatment studies belong to Carroll and her teams; 2022 redevelopment belongs to Liese and Beck; and current meta-analytic estimates belong to the investigators who performed those reviews. A responsible history credits these separate contributions while explaining the intellectual connection among them.

Scientific significance and contemporary appraisal

Cognitive Therapy of Substance Abuse helped articulate an influential bridge between Beck's cognitive therapy and addiction-focused clinical practice. Its distinct historical contribution was to specify anticipatory, relief-oriented, and permissive beliefs as clinically relevant moments in the progression from trigger and craving toward use, then integrate that analysis with collaborative formulation and practical skills. The four-author manual made those ideas usable within a treatment relationship and gave later researchers a concrete set of hypotheses to investigate. Wright et al., 1993; Beck et al., 1993.

From a contemporary perspective, the book's significance lies in the testable questions it established and the clinical practices it organized. The effectiveness of modern CBT for substance use disorders is supported by a much broader empirical literature, though evidence varies and active treatments can yield comparable results. The historical model remains a useful lens for understanding anticipated benefits, distress relief, and rationalizations in the patient's own account. Its responsible application takes place within integrated, substance-specific, medically informed care, informed by the patient's goals and the strongest available evidence. Magill et al., 2026; Liese and Beck, 2022.

Related Articles

Aaron T. Beck — A scientific overview of Beck's life, cognitive therapy, research collaborations, assessment tools, and long-term intellectual influence.

Aaron T. Beck's Cognitive Therapy: Origins, Principles, and Methods — Examines the general methodological foundations from which the four-author addiction model developed.

Cognitive Behavioral Therapy for Substance Use Disorders — Surveys contemporary disorder-focused CBT effectiveness, mechanisms, and treatment delivery beyond the specific 1993 book.

Aaron T. Beck's Collaborative Empiricism and Guided Discovery — Studies the collaborative hypothesis-testing stance central to Beck's therapeutic tradition.

Aaron T. Beck's Cognitive Restructuring and Thought Records — Explains cognitive restructuring and the development of thought records.

References

American Society of Addiction Medicine. (2020). The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. ASAM official guideline.

American Society of Addiction Medicine and American Academy of Addiction Psychiatry. (2024). The ASAM/AAAP clinical practice guideline on the management of stimulant use disorder. Full text.

Beck, A. T., Wright, F. D., Newman, C. F., and Liese, B. S. (1993). Cognitive Therapy of Substance Abuse. Guilford Press. ISBN 9780898621150. Bibliographic record.

Boness, C. L., Votaw, V. R., Schwebel, F. J., Moniz-Lewis, D. I. K., McHugh, R. K., and Witkiewitz, K. (2023). An evaluation of cognitive behavioral therapy for substance use disorder: A systematic review and application of the Society of Clinical Psychology criteria for empirically supported treatments. Clinical Psychology: Science and Practice, 30(2), 129–142. DOI: 10.1037/cps0000131.

Carroll, K. M., Ball, S. A., Martino, S., Nich, C., Babuscio, T. A., Nuro, K. F., Gordon, M. A., Portnoy, G. A., and Rounsaville, B. J. (2008). Computer-assisted delivery of cognitive-behavioral therapy for addiction: A randomized trial of CBT4CBT. American Journal of Psychiatry, 165(7), 881–888. DOI: 10.1176/appi.ajp.2008.07111835.

Carroll, K. M., Fenton, L. R., Ball, S. A., Nich, C., Frankforter, T. L., Shi, J., and Rounsaville, B. J. (2004). Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: A randomized placebo-controlled trial. Archives of General Psychiatry, 61(3), 264–272. DOI: 10.1001/archpsyc.61.3.264.

Carroll, K. M., Nich, C., Ball, S. A., McCance, E., and Rounsaville, B. J. (1998). Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction, 93(5), 713–727. DOI: 10.1046/j.1360-0443.1998.9357137.x.

Carroll, K. M., and colleagues. (2009). Enduring effects of a computer-assisted training program for cognitive behavioral therapy: A 6-month follow-up of CBT4CBT. Drug and Alcohol Dependence. DOI: 10.1016/j.drugalcdep.2008.09.015.

Kiluk, B. D., and colleagues. (2018). Randomized clinical trial of computerized cognitive behavioral therapy and clinician-delivered CBT in comparison with standard outpatient treatment for substance use disorders: Primary within-treatment and follow-up outcomes. JAMA Psychiatry. PubMed.

Liese, B. S., and Beck, A. T. (2022). Cognitive-Behavioral Therapy of Addictive Disorders. Guilford Press. ISBN 9781462548842. Publisher.

Magill, M., and colleagues. (2025). Cognitive-behavioral interventions for co-occurring substance use and mental health disorders: A meta-analysis of consumption and psychosocial functioning. Drug and Alcohol Dependence, 274, 112756. DOI: 10.1016/j.drugalcdep.2025.112756.

Magill, M., Nichols, L. M., Kiluk, B. D., Alton, E., Tartak, O., and Ray, L. A. (2026). A meta-analysis of cognitive behavioral therapy for substance use disorder: Treatment effects by comparator type and consumption and psychosocial outcomes. Behaviour Research and Therapy, 203, 105101. DOI: 10.1016/j.brat.2026.105101.

Ray, L. A., and colleagues. (2020). Combined pharmacotherapy and cognitive behavioral therapy for adults with alcohol or substance use disorders: A systematic review and meta-analysis. JAMA Network Open. Official full text.

Wright, F. D., Beck, A. T., Newman, C. F., and Liese, B. S. (1993). Cognitive therapy of substance abuse: Theoretical rationale. NIDA Research Monograph, 137, 123–146. PMID: 8289917.